Aardvark Therapeutics, Inc. Common Stock (AARD) Stock Price
AARDStock
$7.25−29.58%52W
Market Cap$158.67M
P/E—
PEG Ratio—
Div yield—
Beta3.84
AARD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-56.86%
Price vs S&P 500 (4W)4.11%
VGM Score59.52
AARD Earnings Surprise History
Q2 25-0.66est. -0.60
Q3 25-0.75est. -0.82
Q4 25-0.81est. -0.83
Q1 26-0.99est. -0.91
Q2 26-0.66est. -0.88
AARD Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.11
3.89
3.78
3.78
Industry Peers — Pharmaceuticals(571)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
AARDAardvark Therapeutics, Inc. Common Stock | — | — | C | $7.25 |
| LLYEli Lilly & Co. | D | B | B | $1233.66 |
| JNJJohnson & Johnson | D | C | B | $273.14 |
| ABBVABBVIE INC. | D | C | B | $265.79 |
| MRKMerck & Co., Inc. | D | C | A | $156.45 |
| NVSNovartis AG | C | C | C | $159.98 |
| AZNAstraZeneca PLC | C | B | C | $169.66 |
| NVONovo-Nordisk A/S | B | C | C | $48.66 |
| ABTAbbott Laboratories | C | C | B | $116.13 |
| PFEPfizer Inc. | C | D | C | $28.57 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $552.85 |
About Aardvark Therapeutics, Inc. Common Stock
Aardvark Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapeutics that target Bitter Taste Receptors (TAS2Rs) to treat metabolic and hunger-associated conditions. The company's lead candidate, ARD-101, is an oral gut-restricted TAS2R agonist currently in Phase 3 clinical trials for hyperphagia associated with Prader-Willi Syndrome.